Persistence of immunoglobulin-producing cells in parotid salivary glands of patients with primary Sjögren's syndrome after B cell depletion therapy

Annals of the Rheumatic Diseases

Volumn 71, Issue 11, 2012, Pages 1881-1887

  Hamza, Nishath ^a   Bootsma, Hendrika ^a   Yuvaraj, Saravanan ^a   Spijkervet, Fred K L ^a   Haacke, Erlin A ^a   Pollard, Rodney P E ^a   Visser, Annie ^a   Vissink, Arjan ^a   Kallenberg, Cees G M ^a   Kroese, Frans G M ^a   Bos, Nicolaas A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PLACEBO; RITUXIMAB;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN PRODUCING CELL; IMMUNOHISTOCHEMISTRY; MOLECULAR CLONING; PAROTID GLAND; PRIORITY JOURNAL; RELAPSE; SALIVARY GLAND BIOPSY; SEQUENCE ANALYSIS; SJOEGREN SYNDROME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY-PRODUCING CELLS; B-LYMPHOCYTES; CLONE CELLS; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGIC FACTORS; LYMPHOCYTE DEPLETION; MIDDLE AGED; PAROTID GLAND; SJOGREN'S SYNDROME; YOUNG ADULT;

EID: 84867396543     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2011-201189     Document Type: Article

References (41)

1. Fox RI. Sjögren's syndrome. Lancet 2005;366:321-31.
2. Youinou P, Devauchelle-Pensec V, Pers JO. Significance of B cells and B cell clonality in Sjögren's syndrome. Arthritis Rheum 2010;62:2605-10.
3. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis 2008;67:1541-4.
4. Kallenberg CG, Vissink A, Kroese FG, et al. What have we learned from clinical trials in primary Sjögren's syndrome about pathogenesis? Arthritis Res Ther 2011;13:205.
5. Meiners PM, Vissink A, Kallenberg CG, et al. Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? Expert Opin Biol Ther 2011;11:1381-94.
6. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study. Arthritis Rheum 2005;52:2740-50. (Pubitemid 41369102)
7. Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjögren's syndrome. Arthritis Rheum 2009;60:3251-6.
8. Engel P, Gómez-Puerta JA, Ramos-Casals M, et al. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Pharmacol Rev 2011;63:127-56.
9. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
10. Meijer JM, Pijpe J, Vissink A, et al. Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment. Ann Rheum Dis 2009;68:284-5.
11. Abdulahad WH, Meijer JM, Kroese FG, et al. B cell reconstitution and T helper cell balance after rituximab treatment of active primary Sjögren's syndrome: a doubleblind, placebo-controlled study. Arthritis Rheum 2011;63:1116-23.
12. Rehnberg M, Amu S, Tarkowski A, et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther 2009;11:R123.
13. Gellrich S, Rutz S, Borkowski A, et al. Analysis of V(H)-D-J(H) gene transcripts in B cells infiltrating the salivary glands and lymph node tissues of patients with Sjögren's syndrome. Arthritis Rheum 1999;42:240-7. (Pubitemid 29072840)
14. Hansen A, Gosemann M, Pruss A, et al. Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis Rheum 2004;50:1897-908. (Pubitemid 38725102)
15. Stott DI, Hiepe F, Hummel M, et al. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren's syndrome. J Clin Invest 1998;102:938-46. (Pubitemid 28419239)
16. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American- European Consensus Group. Ann Rheum Dis 2002;61:554-8. (Pubitemid 34539104)
17. Pijpe J, Kalk WW, van der Wal JE, et al. Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sjogren's syndrome. Rheumatology (Oxford) 2007;46:335-41. (Pubitemid 46189797)
18. van Dongen JJ, Langerak AW, Brüggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003;17:2257-317. (Pubitemid 38072572)
19. Yuvaraj S, Dijkstra G, Burgerhof JG, et al. Evidence for local expansion of IgA plasma cell precursors in human ileum. J Immunol 2009;183:4871-8.
20. Giudicelli V, Chaume D, Lefranc MP. IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res 2004;32:W435-40. (Pubitemid 38997372)
21. Giudicelli V, Duroux P, Ginestoux C, et al. IMGT/LIGM-DB, the IMGT comprehensive database of immunoglobulin and T cell receptor nucleotide sequences. Nucleic Acids Res 2006;34:D781-4.
22. Chen Z, Collins AM, Wang Y, et al. Clustering-based identification of clonally-related immunoglobulin gene sequence sets. Immunome Res 2010;6 Suppl 1:S4.
23. Dammers PM, Visser A, Popa ER, et al. Most marginal zone B cells in rat express germline encoded Ig VH genes and are ligand selected. J Immunol 2000;165:6156-69.
24. Dunn-Walters DK, Hackett M, Boursier L, et al. Characteristics of human IgA and IgM genes used by plasma cells in the salivary gland resemble those used in duodenum but not those used in the spleen. J Immunol 2000;164:1595-601. (Pubitemid 30067279)
25. Stoel M, Evenhuis WN, Kroese FG, et al. Rat salivary gland reveals a more restricted IgA repertoire than ileum. Mol Immunol 2008;45:719-27. (Pubitemid 47498582)
26. Bahler DW, Swerdlow SH. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjögren's syndrome) begin as nonmalignant antigenselected expansions. Blood 1998;91:1864-72. (Pubitemid 28185486)
27. Schibler U, Marcu KB, Perry RP. The synthesis and processing of the messenger RNAs specifying heavy and light chain immunoglobulins in MPC-11 cells. Cell 1978;15:1495-509. (Pubitemid 9109706)
28. Ahuja A, Anderson SM, Khalil A, et al. Maintenance of the plasma cell pool is independent of memory B cells. Proc Natl Acad Sci USA 2008;105:4802-7. (Pubitemid 351753827)
29. Jazirehi AR, Vega MI, Bonavida B. Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy. Cancer Res 2007;67:1270-81.
30. Hamaguchi Y, Uchida J, Cain DW, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. J Immunol 2005;174:4389-99. (Pubitemid 40396022)
31. Gong Q, Ou Q, Ye S, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol 2005;174:817-26. (Pubitemid 40094277)
32. Vugmeyster Y, Howell K, McKeever K, et al. Differential in vivo effects of rituximab on two B-cell subsets in cynomolgus monkeys. Int Immunopharmacol 2003;3:1477-81. (Pubitemid 37025728)
33. Anolik JH, Barnard J, Owen T, et al. Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56. (Pubitemid 47502752)
34. Mraz M, Zent CS, Church AK, et al . Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistance. Br J Haematol 2011; 155:53-64.
35. Withers DR, Fiorini C, Fischer RT, et al. T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood 2007;109:4856-64. (Pubitemid 46827782)
36. Hiepe F, Dörner T, Hauser AE, et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 2011;7:170-8.
37. Lund FE, Randall TD. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat Rev Immunol 2010;10:236-47.
38. Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008;67:1011-6. (Pubitemid 351956665)
39. Lu TY, Ng KP, Cambridge G, et al. A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at University College London Hospital: the first fifty patients. Arthritis Rheum 2009;61:482-7.
40. Ng KP, Cambridge G, Leandro MJ, et al. B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-62. (Pubitemid 47309748)
41. Szyszko EA, Brokstad KA, Oijordsbakken G, et al. Salivary glands of primary Sjögren's syndrome patients express factors vital for plasma cell survival. Arthritis Res Ther 2011;13:R2.